Kinetics and dynamics of lorazepam during and after continuous intravenous infusion

OBJECTIVETo evaluate the kinetics and dynamics of lorazepam during administration as a bolus plus an infusion, using electroencephalography as a pharmacodynamic end point. METHODSNine volunteers received a 2-mg bolus loading dose of lorazepam, coincident with the start of a 2 μg/kg/hr zero-order inf...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Critical care medicine 2000-08, Vol.28 (8), p.2750-2757
Hauptverfasser: Greenblatt, David J, von Moltke, Lisa L, Ehrenberg, Bruce L, Harmatz, Jerold S, Corbett, Kathleen E, Wallace, Donald W, Shader, Richard I
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2757
container_issue 8
container_start_page 2750
container_title Critical care medicine
container_volume 28
creator Greenblatt, David J
von Moltke, Lisa L
Ehrenberg, Bruce L
Harmatz, Jerold S
Corbett, Kathleen E
Wallace, Donald W
Shader, Richard I
description OBJECTIVETo evaluate the kinetics and dynamics of lorazepam during administration as a bolus plus an infusion, using electroencephalography as a pharmacodynamic end point. METHODSNine volunteers received a 2-mg bolus loading dose of lorazepam, coincident with the start of a 2 μg/kg/hr zero-order infusion. The infusion was stopped after 4 hrs. Plasma lorazepam concentrations and electroencephalographic activity in the 13- to 30-Hz range were monitored for 24 hrs. RESULTSThe bolus-plus-infusion scheme rapidly produced plasma lorazepam concentrations that were close to those predicted to be achieved at true steady state. Mean kinetic values for lorazepam were as followsvolume of distribution, 126 L; elimination half-life, 13.8 hrs; and clearance, 109 mL/min. Electroencephalographic effects were maximal 0.5 hr after the loading dose, were maintained essentially constant during infusion, and then declined in parallel with plasma concentrations after the infusion was terminated. There was no evidence of tolerance. Plots of pharmacodynamic electroencephalographic effect vs. plasma lorazepam concentration demonstrated counterclockwise hysteresis, consistent with an effect-site equilibration delay. This was incorporated into a kinetic-dynamic model in which hypothetical effect-site concentration was related to pharmacodynamic electroencephalographic effect via the sigmoid Emax model. The analysis yielded the following mean estimatesmaximum electroencephalographic effect, 12.7% over baseline; 50% effective concentration, 13.1 ng/mL; and effect-site equilibration half-life, 8.8 mins. CONCLUSIONDespite the delay in effect onset, continuous infusion of lorazepam, preceded by a bolus loading dose, produces a relatively constant sedative effect on the central nervous system, which can be utilized in the context of critical care medicine.
doi_str_mv 10.1097/00003246-200008000-00011
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72218921</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72218921</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3851-7c826579ce014165c8a2529e5651ea729ef095c96ee3792ac23b98cc2050dcff3</originalsourceid><addsrcrecordid>eNp1kctOwzAQRS0EoqXwCygLxC7gR5zES4R4iUosgLXlOmNqSJxiJ1Tl63Gb8thgaeQ70rnj0TVCCcFnBIviHMfDaJandK3KWGksQnbQmHAWGyrYLhpjLHDKMsFG6CCE10hkvGD7aBSH5Hn0j9HjvXXQWR0S5aqkWjnVrJvWJHXr1ScsVJNUvbfuZQMo04FPdOs66_q2D4l1nVcf4AZt-mBbd4j2jKoDHG3vCXq-vnq6vE2nDzd3lxfTVLOSk7TQJc15ITTEvUjOdakopwJ4zgmoIiqDBdciB2CFoEpTNhOl1hRzXGlj2ASdDnMXvn3vIXSysUFDXSsHcR9ZUEpKQUkEywHUvg3Bg5ELbxvlV5JguQ5UfgcqfwKVm0Cj9Xj7Rj9roPpjHBKMwMkWUEGr2njltA2_XMYZF2XEsgFbtnWMMLzV_RK8nIOqu7n87z_ZF8-yjR0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72218921</pqid></control><display><type>article</type><title>Kinetics and dynamics of lorazepam during and after continuous intravenous infusion</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Greenblatt, David J ; von Moltke, Lisa L ; Ehrenberg, Bruce L ; Harmatz, Jerold S ; Corbett, Kathleen E ; Wallace, Donald W ; Shader, Richard I</creator><creatorcontrib>Greenblatt, David J ; von Moltke, Lisa L ; Ehrenberg, Bruce L ; Harmatz, Jerold S ; Corbett, Kathleen E ; Wallace, Donald W ; Shader, Richard I</creatorcontrib><description>OBJECTIVETo evaluate the kinetics and dynamics of lorazepam during administration as a bolus plus an infusion, using electroencephalography as a pharmacodynamic end point. METHODSNine volunteers received a 2-mg bolus loading dose of lorazepam, coincident with the start of a 2 μg/kg/hr zero-order infusion. The infusion was stopped after 4 hrs. Plasma lorazepam concentrations and electroencephalographic activity in the 13- to 30-Hz range were monitored for 24 hrs. RESULTSThe bolus-plus-infusion scheme rapidly produced plasma lorazepam concentrations that were close to those predicted to be achieved at true steady state. Mean kinetic values for lorazepam were as followsvolume of distribution, 126 L; elimination half-life, 13.8 hrs; and clearance, 109 mL/min. Electroencephalographic effects were maximal 0.5 hr after the loading dose, were maintained essentially constant during infusion, and then declined in parallel with plasma concentrations after the infusion was terminated. There was no evidence of tolerance. Plots of pharmacodynamic electroencephalographic effect vs. plasma lorazepam concentration demonstrated counterclockwise hysteresis, consistent with an effect-site equilibration delay. This was incorporated into a kinetic-dynamic model in which hypothetical effect-site concentration was related to pharmacodynamic electroencephalographic effect via the sigmoid Emax model. The analysis yielded the following mean estimatesmaximum electroencephalographic effect, 12.7% over baseline; 50% effective concentration, 13.1 ng/mL; and effect-site equilibration half-life, 8.8 mins. CONCLUSIONDespite the delay in effect onset, continuous infusion of lorazepam, preceded by a bolus loading dose, produces a relatively constant sedative effect on the central nervous system, which can be utilized in the context of critical care medicine.</description><identifier>ISSN: 0090-3493</identifier><identifier>EISSN: 1530-0293</identifier><identifier>DOI: 10.1097/00003246-200008000-00011</identifier><identifier>PMID: 10966246</identifier><identifier>CODEN: CCMDC7</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams &amp; Wilkins, Inc</publisher><subject>Adult ; Biological and medical sciences ; Electroencephalography ; Gabaergic and benzodiazepinic system ; Humans ; Hypnotics and Sedatives - administration &amp; dosage ; Hypnotics and Sedatives - pharmacokinetics ; Infusions, Intravenous ; Lorazepam - administration &amp; dosage ; Lorazepam - pharmacokinetics ; Male ; Medical sciences ; Middle Aged ; Neuropharmacology ; Neurotransmitters. Neurotransmission. Receptors ; Pharmacology. Drug treatments</subject><ispartof>Critical care medicine, 2000-08, Vol.28 (8), p.2750-2757</ispartof><rights>2000 Lippincott Williams &amp; Wilkins, Inc.</rights><rights>2000 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3851-7c826579ce014165c8a2529e5651ea729ef095c96ee3792ac23b98cc2050dcff3</citedby><cites>FETCH-LOGICAL-c3851-7c826579ce014165c8a2529e5651ea729ef095c96ee3792ac23b98cc2050dcff3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=1453598$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10966246$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Greenblatt, David J</creatorcontrib><creatorcontrib>von Moltke, Lisa L</creatorcontrib><creatorcontrib>Ehrenberg, Bruce L</creatorcontrib><creatorcontrib>Harmatz, Jerold S</creatorcontrib><creatorcontrib>Corbett, Kathleen E</creatorcontrib><creatorcontrib>Wallace, Donald W</creatorcontrib><creatorcontrib>Shader, Richard I</creatorcontrib><title>Kinetics and dynamics of lorazepam during and after continuous intravenous infusion</title><title>Critical care medicine</title><addtitle>Crit Care Med</addtitle><description>OBJECTIVETo evaluate the kinetics and dynamics of lorazepam during administration as a bolus plus an infusion, using electroencephalography as a pharmacodynamic end point. METHODSNine volunteers received a 2-mg bolus loading dose of lorazepam, coincident with the start of a 2 μg/kg/hr zero-order infusion. The infusion was stopped after 4 hrs. Plasma lorazepam concentrations and electroencephalographic activity in the 13- to 30-Hz range were monitored for 24 hrs. RESULTSThe bolus-plus-infusion scheme rapidly produced plasma lorazepam concentrations that were close to those predicted to be achieved at true steady state. Mean kinetic values for lorazepam were as followsvolume of distribution, 126 L; elimination half-life, 13.8 hrs; and clearance, 109 mL/min. Electroencephalographic effects were maximal 0.5 hr after the loading dose, were maintained essentially constant during infusion, and then declined in parallel with plasma concentrations after the infusion was terminated. There was no evidence of tolerance. Plots of pharmacodynamic electroencephalographic effect vs. plasma lorazepam concentration demonstrated counterclockwise hysteresis, consistent with an effect-site equilibration delay. This was incorporated into a kinetic-dynamic model in which hypothetical effect-site concentration was related to pharmacodynamic electroencephalographic effect via the sigmoid Emax model. The analysis yielded the following mean estimatesmaximum electroencephalographic effect, 12.7% over baseline; 50% effective concentration, 13.1 ng/mL; and effect-site equilibration half-life, 8.8 mins. CONCLUSIONDespite the delay in effect onset, continuous infusion of lorazepam, preceded by a bolus loading dose, produces a relatively constant sedative effect on the central nervous system, which can be utilized in the context of critical care medicine.</description><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Electroencephalography</subject><subject>Gabaergic and benzodiazepinic system</subject><subject>Humans</subject><subject>Hypnotics and Sedatives - administration &amp; dosage</subject><subject>Hypnotics and Sedatives - pharmacokinetics</subject><subject>Infusions, Intravenous</subject><subject>Lorazepam - administration &amp; dosage</subject><subject>Lorazepam - pharmacokinetics</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neuropharmacology</subject><subject>Neurotransmitters. Neurotransmission. Receptors</subject><subject>Pharmacology. Drug treatments</subject><issn>0090-3493</issn><issn>1530-0293</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kctOwzAQRS0EoqXwCygLxC7gR5zES4R4iUosgLXlOmNqSJxiJ1Tl63Gb8thgaeQ70rnj0TVCCcFnBIviHMfDaJandK3KWGksQnbQmHAWGyrYLhpjLHDKMsFG6CCE10hkvGD7aBSH5Hn0j9HjvXXQWR0S5aqkWjnVrJvWJHXr1ScsVJNUvbfuZQMo04FPdOs66_q2D4l1nVcf4AZt-mBbd4j2jKoDHG3vCXq-vnq6vE2nDzd3lxfTVLOSk7TQJc15ITTEvUjOdakopwJ4zgmoIiqDBdciB2CFoEpTNhOl1hRzXGlj2ASdDnMXvn3vIXSysUFDXSsHcR9ZUEpKQUkEywHUvg3Bg5ELbxvlV5JguQ5UfgcqfwKVm0Cj9Xj7Rj9roPpjHBKMwMkWUEGr2njltA2_XMYZF2XEsgFbtnWMMLzV_RK8nIOqu7n87z_ZF8-yjR0</recordid><startdate>200008</startdate><enddate>200008</enddate><creator>Greenblatt, David J</creator><creator>von Moltke, Lisa L</creator><creator>Ehrenberg, Bruce L</creator><creator>Harmatz, Jerold S</creator><creator>Corbett, Kathleen E</creator><creator>Wallace, Donald W</creator><creator>Shader, Richard I</creator><general>Lippincott Williams &amp; Wilkins, Inc</general><general>Lippincott</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200008</creationdate><title>Kinetics and dynamics of lorazepam during and after continuous intravenous infusion</title><author>Greenblatt, David J ; von Moltke, Lisa L ; Ehrenberg, Bruce L ; Harmatz, Jerold S ; Corbett, Kathleen E ; Wallace, Donald W ; Shader, Richard I</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3851-7c826579ce014165c8a2529e5651ea729ef095c96ee3792ac23b98cc2050dcff3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Electroencephalography</topic><topic>Gabaergic and benzodiazepinic system</topic><topic>Humans</topic><topic>Hypnotics and Sedatives - administration &amp; dosage</topic><topic>Hypnotics and Sedatives - pharmacokinetics</topic><topic>Infusions, Intravenous</topic><topic>Lorazepam - administration &amp; dosage</topic><topic>Lorazepam - pharmacokinetics</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neuropharmacology</topic><topic>Neurotransmitters. Neurotransmission. Receptors</topic><topic>Pharmacology. Drug treatments</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Greenblatt, David J</creatorcontrib><creatorcontrib>von Moltke, Lisa L</creatorcontrib><creatorcontrib>Ehrenberg, Bruce L</creatorcontrib><creatorcontrib>Harmatz, Jerold S</creatorcontrib><creatorcontrib>Corbett, Kathleen E</creatorcontrib><creatorcontrib>Wallace, Donald W</creatorcontrib><creatorcontrib>Shader, Richard I</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Critical care medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Greenblatt, David J</au><au>von Moltke, Lisa L</au><au>Ehrenberg, Bruce L</au><au>Harmatz, Jerold S</au><au>Corbett, Kathleen E</au><au>Wallace, Donald W</au><au>Shader, Richard I</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Kinetics and dynamics of lorazepam during and after continuous intravenous infusion</atitle><jtitle>Critical care medicine</jtitle><addtitle>Crit Care Med</addtitle><date>2000-08</date><risdate>2000</risdate><volume>28</volume><issue>8</issue><spage>2750</spage><epage>2757</epage><pages>2750-2757</pages><issn>0090-3493</issn><eissn>1530-0293</eissn><coden>CCMDC7</coden><abstract>OBJECTIVETo evaluate the kinetics and dynamics of lorazepam during administration as a bolus plus an infusion, using electroencephalography as a pharmacodynamic end point. METHODSNine volunteers received a 2-mg bolus loading dose of lorazepam, coincident with the start of a 2 μg/kg/hr zero-order infusion. The infusion was stopped after 4 hrs. Plasma lorazepam concentrations and electroencephalographic activity in the 13- to 30-Hz range were monitored for 24 hrs. RESULTSThe bolus-plus-infusion scheme rapidly produced plasma lorazepam concentrations that were close to those predicted to be achieved at true steady state. Mean kinetic values for lorazepam were as followsvolume of distribution, 126 L; elimination half-life, 13.8 hrs; and clearance, 109 mL/min. Electroencephalographic effects were maximal 0.5 hr after the loading dose, were maintained essentially constant during infusion, and then declined in parallel with plasma concentrations after the infusion was terminated. There was no evidence of tolerance. Plots of pharmacodynamic electroencephalographic effect vs. plasma lorazepam concentration demonstrated counterclockwise hysteresis, consistent with an effect-site equilibration delay. This was incorporated into a kinetic-dynamic model in which hypothetical effect-site concentration was related to pharmacodynamic electroencephalographic effect via the sigmoid Emax model. The analysis yielded the following mean estimatesmaximum electroencephalographic effect, 12.7% over baseline; 50% effective concentration, 13.1 ng/mL; and effect-site equilibration half-life, 8.8 mins. CONCLUSIONDespite the delay in effect onset, continuous infusion of lorazepam, preceded by a bolus loading dose, produces a relatively constant sedative effect on the central nervous system, which can be utilized in the context of critical care medicine.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams &amp; Wilkins, Inc</pub><pmid>10966246</pmid><doi>10.1097/00003246-200008000-00011</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0090-3493
ispartof Critical care medicine, 2000-08, Vol.28 (8), p.2750-2757
issn 0090-3493
1530-0293
language eng
recordid cdi_proquest_miscellaneous_72218921
source MEDLINE; Journals@Ovid Complete
subjects Adult
Biological and medical sciences
Electroencephalography
Gabaergic and benzodiazepinic system
Humans
Hypnotics and Sedatives - administration & dosage
Hypnotics and Sedatives - pharmacokinetics
Infusions, Intravenous
Lorazepam - administration & dosage
Lorazepam - pharmacokinetics
Male
Medical sciences
Middle Aged
Neuropharmacology
Neurotransmitters. Neurotransmission. Receptors
Pharmacology. Drug treatments
title Kinetics and dynamics of lorazepam during and after continuous intravenous infusion
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T12%3A22%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Kinetics%20and%20dynamics%20of%20lorazepam%20during%20and%20after%20continuous%20intravenous%20infusion&rft.jtitle=Critical%20care%20medicine&rft.au=Greenblatt,%20David%20J&rft.date=2000-08&rft.volume=28&rft.issue=8&rft.spage=2750&rft.epage=2757&rft.pages=2750-2757&rft.issn=0090-3493&rft.eissn=1530-0293&rft.coden=CCMDC7&rft_id=info:doi/10.1097/00003246-200008000-00011&rft_dat=%3Cproquest_cross%3E72218921%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72218921&rft_id=info:pmid/10966246&rfr_iscdi=true